Longitudinal Cognitive Decline in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer’s Disease - 21/11/24

Doi : 10.14283/jpad.2021.64

Yen Ying Lim ^1,^7,^⁎ , J. Kong ², P. Maruff ^3,⁴, J. Jaeger ^5,⁶, E. Huang ², E. Ratti ²

¹ Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Australia

² Biogen, Cambridge, MA, USA

³ Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia

⁴ Cogstate Ltd., Melbourne, Australia

⁵ CognitionMetrics, Inc, Wilmington, Delaware, USA

⁶ Albert Einstein College of Medicine, New York, NY, USA

⁷ Turner Institute for Brain and Mental Health, 18 Innovation Walk, 3168, Clayton, VIC, Australia

^a yenying.lim@monash.edu yenying.lim@monash.edu

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Sensitive cognitive assessments accurately detect and track cognitive decline in Alzheimer’s disease. The Cogstate battery was used to measure cognitive change in cognitively normal participants and in individuals with mild cognitive impairment and mild Alzheimer’s disease enrolled in the Australian Imaging, Biomarker and Lifestyle Rate of Change Substudy. Over 18 months, verbal episodic memory performance declined for mild cognitive impairment and mild Alzeheimer’s disease groups when compared to cognitively normal participants. Frequent assessments of episodic memory may facilitate early detection of cognitive decline due to Alzheimer’s disease.

Le texte complet de cet article est disponible en PDF.

Keywords : Alzheimer’s disease, mild cognitive impairment, Cogstate Brief Battery, International Shopping List Test, cognitive decline